Amicus Therapeutics Inc. [NASDAQ: FOLD] closed the trading session at $12.68 on 03/02/23. The day’s price range saw the stock hit a low of $12.545, while the highest price level was $13.53. The company report on March 1, 2023 that Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
2022 Revenue Growth of 16% at CER to $329M.
Projecting Galafold Revenue Growth in 2023 of 12-17% at CER.
The stocks have a year to date performance of 3.85 percent and weekly performance of -2.76 percent. The stock has been moved at 12.31 percent over the last six months. The stock has performed -2.76 percent around the most recent 30 days and changed 10.45 percent over the most recent 3-months.
If compared to the average trading volume of 2.10M shares, FOLD reached to a volume of 3317156 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc. [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $14.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on September 09, 2022. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on April 13, 2022, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise from $12 to $16, while SVB Leerink kept a Outperform rating on FOLD stock. On November 15, 2021, analysts increased their price target for FOLD shares from 12 to 16.
The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 0.51, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 11.11. The Price to Book ratio for the last quarter was 27.57, with the Price to Cash per share for the same quarter was set at 1.25.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc. [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.76. With this latest performance, FOLD shares dropped by -2.76% in over the last four-week period, additionally plugging by 12.31% over the last 6 months – not to mention a rise of 54.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 46.91, with the RSI for the last a single of trading hit 43.34, and the three-weeks RSI is set at 49.18 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 12.60, while it was recorded at 13.10 for the last single week of trading, and 11.11 for the last 200 days.
Amicus Therapeutics Inc. [FOLD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc. [FOLD] shares currently have an operating margin of -65.44 and a Gross Margin at +86.69. Amicus Therapeutics Inc.’s Net Margin is presently recorded at -81.98.
Return on Equity for this stock declined to -84.37, with Return on Assets sitting at -27.96.
Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.80.
Amicus Therapeutics Inc. [FOLD]: Insider Ownership positions
There are presently around $3,708 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: PERCEPTIVE ADVISORS LLC with ownership of 27,642,917, which is approximately 0.986% of the company’s market cap and around 0.80% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 26,800,000 shares of the stock with an approximate value of $339.82 million in FOLD stocks shares; and VANGUARD GROUP INC, currently with $336.51 million in FOLD stock with ownership of nearly 2.579% of the company’s market capitalization.
Positions in Amicus Therapeutics Inc. stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 133 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 18,511,157 shares. Additionally, 100 investors decreased positions by around 18,072,294 shares, while 33 investors held positions by with 255,840,481 shares. The mentioned changes placed institutional holdings at 292,423,932 shares, according to the latest SEC report filing. FOLD stock had 42 new institutional investments in for a total of 2,808,960 shares, while 34 institutional investors sold positions of 7,266,960 shares during the same period.